Cancer Genetics, Inc. has officially rebranded as Vyant Bio, Inc. following the closure of its merger with StemoniX, effective March 30, 2021. The company will begin trading on Nasdaq under the new symbol VYNT on March 31, 2021. This merger aims to create a leading biotechnology platform, combining innovative drug discovery techniques and human-powered systems to enhance preclinical and clinical pipelines. The merger resulted in issuing approximately 17.98 million shares to StemoniX shareholders and establishing a streamlined leadership team to drive future growth.
Cancer Genetics, Inc. (CGIX) held a shareholder meeting on March 24, 2021, where stockholders overwhelmingly approved the merger with StemoniX, Inc. This merger aims to create an innovative platform that enhances drug discovery and development capabilities in collaboration with biopharma partners. The approval included the issuance of common stock and a reverse stock split, alongside the establishment of an equity incentive plan. CEO Jay Roberts expressed gratitude for stakeholder support and highlighted the merger's strategic importance.
Cancer Genetics (CGIX) has appointed Dr. Roland J. Carrillo as Vice President of Business Development, effective March 18, 2021. Dr. Carrillo brings over a decade of experience in drug discovery and business development, previously holding senior roles at Crown Bioscience, BellBrook Labs, and The Jackson Laboratory. He holds an MBA in Bioscience Management and a PhD in Quantitative Genetics. His expertise is anticipated to be pivotal as CGIX prepares for its merger with StemoniX, aiming for exponential growth in drug discovery and development, according to CEO Jay Roberts.
Cancer Genetics (Nasdaq: CGIX) announced that CEO Jay Roberts will present at the Annual 33rd ROTH Conference virtually from March 15-17, 2021. In his presentation, Roberts will discuss the company's transformational business strategy and the proposed merger with StemoniX, Inc.. Investors can register for the conference and schedule one-on-one meetings with the company. Cancer Genetics focuses on precision and translational medicine to support drug discovery through its vivoPharm subsidiary.
Cancer Genetics (Nasdaq: CGIX) announced that CEO Jay Roberts will present at the H.C. Wainwright’s Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. The presentation will cover the Company’s recent transformational business strategy and the proposed merger with StemoniX, Inc.
On-demand access begins at 7:00 am ET on March 9 and ends at 7:00 pm ET on March 10. Interested institutional investors can register for the event online.
Cancer Genetics, Inc. (Nasdaq: CGIX) announced the closure of its registered direct offering of 2,777,778 shares at $6.30 per share, raising approximately $17.5 million. The gross proceeds will support general corporate purposes, including working capital, and are expected to aid the planned merger with StemoniX, pending stockholder approval. The offering utilized a 'shelf' registration statement and involved placement agent H.C. Wainwright & Co. The company focuses on drug discovery and precision medicine through its subsidiary, vivoPharm.
Cancer Genetics (Nasdaq: CGIX) announced a plans to raise approximately $17.5 million through a registered direct offering of 2,777,778 shares at $6.30 per share. The offering, expected to close on or around February 16, 2021, is aimed at general corporate purposes, including working capital and capital expenditures, and is tied to the anticipated merger with StemoniX, pending stockholder approval. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Cancer Genetics, Inc. (Nasdaq: CGIX) has successfully closed a private placement, raising approximately $10.0 million through the issuance of 2,758,624 shares of common stock and associated warrants at $3.625 per share. The accompanying warrants, exercisable at $3.50 for five and a half years, are expected to support the company’s operations and its upcoming merger with StemoniX, pending stockholder approval. The proceeds will be utilized for general corporate purposes, including working capital.
Cancer Genetics, Inc. (Nasdaq: CGIX) announced a private placement to raise approximately $10.0 million by issuing 2,758,624 shares of common stock and associated warrants at a purchase price of $3.625 per share. The closing is expected on February 1, 2021, subject to customary conditions. Proceeds will support general corporate purposes and be available for the upcoming merger with StemoniX, pending stockholder approval. The warrants are exercisable at $3.50 per share and have a term of five and a half years.
Cancer Genetics, a leader in drug discovery, announced CEO Jay Roberts will present at the 2021 BioConnect Virtual Conference from January 11-14, 2021. The conference will highlight the Company’s new business strategy and its proposed merger with StemoniX, Inc. The on-demand presentation will be accessible starting January 11 at 6:00 am ET until January 14 at 9:00 pm ET. CGIX will also hold virtual 1:1 meetings during and after the event. For more information, visit www.cancergenetics.com.